Advanced Prostate cancer treatment

Mr Stephen James following his second treatment with Lutetium – the 100th treatment at Wesley Medical Imaging.

Another advanced prostate cancer treatment milestone has been reached at Uniting Care Medical Imaging’s (UCMI) Wesley Medical Imaging clinic.

In August 2017, UCMI completed the first Queensland Lutetium 177 PSMA Therapy for advanced prostate cancer.

On the 13 September 2018, UCMI administered the 100th treatment to hopeful men in their quest to fight the disease. This is an exciting milestone for UCMI and also for the Queensland community who has access to this treatment.

About Lutetium-177 PSMA

Lutetium-177 PSMA is a new type of theranostics treatment for advanced prostate cancer. The treatment works by delivering an injection of therapeutic radiation directly to the prostate cancer and its metastases.

This non-invasive prostate cancer treatment aims to reduce the size of the tumour/s and stop them from multiplying and as a result easing the symptoms caused by the tumours. Furthermore in the majority of cases, Lutetium 177 PSMA therapy stabilises or improves disease that has previously been progressive.

Advanced Prostate cancer treatment patient

Mr John Little enjoying a piece of cake after his second Lutetium treatment – the 101st treatment at Wesley Medical Imaging.

Professor David Wong leads a dedicated team treating men with Lutetium-177 PSMA treatment for advanced prostate cancer.

About Theranostics Treatments

Lutetium-177 PSMA is part of the broader portfolio of Theranostics treatments. Unitingcare Medical Imaging offers a range of Theranostic treatments for other disease processes.